Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study;Efectos de dabigatran en el cociente internacional normalizado, tiempo de tromboplastina parcial activada, tiempo de trombina y fibrinógeno: Estudio multicéntrico, in vitro

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1627-1636

  Dager, William E ^a,b,c   Gosselin, Robert C ^c   Kitchen, Steve ^d   Dwyre, Dennis ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Activated partial thromboplastin time; Dabigatran; Fibrinogen; International normalized ratio; Thrombin time

Indexed keywords

DABIGATRAN; FIBRINOGEN; REAGENT;

ARTICLE; ASSAY; CANADA; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; THROMBIN TIME; UNITED KINGDOM; UNITED STATES;

ANTITHROMBINS; BENZIMIDAZOLES; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; GREAT BRITAIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRODRUGS; PYRIDINES; REPRODUCIBILITY OF RESULTS; THROMBIN TIME; UNITED STATES;

EID: 84872258441     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R179     Document Type: Article

References (25)

1. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424
2. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(suppl 1):9S-16S. doi: 10.1177/1076029609343004
3. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. doi: 10.1056/NEJMoa0905561
4. Friedman RJ, Dahl OE, Rosencher N, et al.; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:175-82. doi: 10.1016/j.thromres.2010.03.021
5. Schulman S, Kearon C, Kakkar AK, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52. doi: 10.1056/NEJMoa0906598
6. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-43. doi: 10.1007/s11239-011-0561-1
7. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64:956-67. doi: 10.1111/j.1742-1241.2009.02286.x
8. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27. doi: 10.1160/TH09-11-0758
9. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. doi: 10.1111/j.1365-2125.2007.02899.x
10. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45:555-63. doi: 10.1177/0091270005274550
11. FDA. Briefing information, dabigatran etexilate mesylate capsules, for the September 20, 2010, meeting of the cardiovascular and renal drugs advisory committee www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf (accessed 2012 Feb 16).
12. Lindahl TL, Baghaei F, Blixter IF, et al. Expert group on coagulation of the external quality assurance in laboratory medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8. doi: 10.1160/TH10-06-0342
13. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007;98:155-62. doi: 10.1160/TH07-03-0183
14. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011;127:457-65. doi: 10.1016/j.thromres.2011.01.001
15. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010;85:185-7. doi: 10.1002/ajh.21607
16. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-72. doi: 10.1515/CCLM.2011.134
17. Levy JH, Azran M. Anesthetic concerns for patients with coagulopathy. Curr Opin Anaesthesiol 2010;23:400-5. doi: 10.1097/ACO.0b013e328339480a
18. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran- treated patients. Ann Pharmacother 2011;45:e40. doi: 10.1345/aph.1Q105
19. Deremer CE, Gujral JS, Thornton JW, Sorrentino RA. Dabigatran falsely elevates point of care international normalized ratio results. Am J Med 2011;124:e5-6. doi:10.1016/j.amjmed.2011.02.009
20. Eby CS, Hollensead CS, Adcock DM, et al. CGL-A participant summary. 2012 College of American Pathologists. Northfield, IL.
21. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012;125:417-20. doi: 10.1016/j.amjmed.2011.10.017
22. Walker ID, Woods AL. United Kingdom national external quality assessment scheme (UK NEQAS) for blood coagulation. Report on survey 189, August 2011. Sheffield, UK.
23. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007;98:234-42. doi: 10.1160/TH06-10-0607
24. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43. doi: 10.1097/MBC.0b013e32834f1b0c
25. Guy S, Kitchen S, Laidlaw S, Cooper P, Woolley A, Maclean R. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol 2008;142:466-8. doi: 10.1111/j.1365-2141.2008.07204.x